Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Enanta Pharmaceuticals Inc

ENTA ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$12.52

▼ -1.42%

Market Cap $364.65M · Vol 78.92K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$364.65M

Small Cap

Div Yield

N/A

EPS Growth

+38.54%

YoY

RSI (14)

36.03

Momentum

Beta

0.97

vs Market

52W High

$17.12

25.82% below

52W Low

$7.05

80.14% above

Volume

78.92K

Avg 84.60K

P/B

3.96

Price-to-book

ROE

-84.63%

Return on equity

Free Float

95.15%

Public shares

Shariah Compliance8 STANDARDS

✗ Enanta Pharmaceuticals Inc (ENTA) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ENTA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.42%

-2.42%

-0.95%

-5.65%

YTD

-20.61%

+66.05%

-1.65%

-78.57%

Financials & Valuation

TTM · Annual

Total Revenue	$65.32M
Net Income	$-81,889,000.00
Revenue Growth (YoY)	-21.60%
Gross Margin	100.00%
Operating Margin	-130.65%
Net Profit Margin	-125.36%
ROE	-84.63%
ROA · ROIC	-25.42% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	3.91
P/B	3.96
P/FCF	N/A
EPS Growth	+38.54%
Outstanding Shares	29.13M

Technical Indicators

50-Day SMA	$13.31
200-Day SMA	$13.60
RSI (14)	36.03
Beta	0.97
52-Week High	$17.12
52-Week Low	$7.05

Volume Today	78.92K
Avg Daily Volume (30D)	84.60K
Relative Volume	0.93x
Volatility (10D)	46.48
Volatility (30D)	41.74
Free Float	95.15%

Analyst Consensus

BUY

Current Price $12.52

Mean Target $22.40

52W Low$7.05 52W High$17.12

Current

Target

$7.05 $17.12

Current Analyst target

+78.91% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001V9NSC3

ISINUS29251M1062

CountryUSA

Sub-IndustryBiopharmaceuticals

Earnings DateNov 16, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. +1.92% CSL.AX CSL Limited +1.81% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. -0.92% UCB.BR Ucb SA +1.21% BIIB Biogen Inc. +1.41%

Company Profile

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.